Biogen Inc.

Biogen Inc. is a global biotechnology company specializing in the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen is a pioneer in multiple sclerosis (MS) treatments and has expanded into Alzheimer's disease, spinal muscular atrophy (SMA), and other rare neurological conditions. The company's portfolio includes blockbuster drugs like Tecfidera, Tysabri, and Spinraza, as well as Aduhelm and Leqembi for Alzheimer's. Biogen operates through a single segment: Biogen, which includes its core neurology business and biosimilars.

Biogen generates revenue primarily from the sale of prescription drugs, with multiple sclerosis therapies accounting for the majority of sales. Key products include Tecfidera (oral MS treatment), Tysabri (infusion for MS), and Vumerity (oral MS). Spinraza is the leading treatment for SMA, while Leqembi (developed with Eisai) targets early Alzheimer's. The company also has a biosimilars portfolio (e.g., Benepali, Flixabi) that contributes modestly. Revenue is recognized upon product shipment, and the company invests heavily in R&D to sustain its pipeline.

Biogen operates in the highly competitive drug manufacturing industry, specifically within neurology and rare diseases. Its main competitors include Roche, Novartis, Merck KGaA, and Sanofi in MS; and Roche, Novartis, and Eli Lilly in Alzheimer's. Biogen's competitive advantage lies in its deep expertise in neurology and a strong pipeline of gene therapies and antisense oligonucleotides. However, it faces challenges from generic competition for Tecfidera and pricing pressures. The company's market cap of $28.93B and PE of 20.77 reflect its moderate growth profile.

Biogen's primary customers are healthcare providers, including neurologists, hospitals, and specialty pharmacies. Patients with MS, SMA, Alzheimer's, and other neurological disorders are the end users. Geographically, the US is the largest market (over 60% of revenue), followed by Europe and other international markets. The company's drugs are often prescribed by specialists and require patient support programs. Biogen also collaborates with academic institutions and biotech firms to advance its pipeline.

An auto-generated descriptive profile based on company data, for informational purposes only.